Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
09 mai 2023 16h00 HE
|
Prometheus Biosciences
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
16 avr. 2023 06h00 HE
|
Prometheus Biosciences
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and...
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
09 mars 2023 08h30 HE
|
Prometheus Biosciences
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
28 févr. 2023 16h00 HE
|
Prometheus Biosciences
– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – – Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 – ...
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
22 févr. 2023 16h00 HE
|
Prometheus Biosciences
- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3rd - - Oral Presentation on ARTEMIS-UC Phase 2 primary and secondary endpoint data from...
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
09 févr. 2023 16h00 HE
|
Prometheus Biosciences
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 08h30 HE
|
Prometheus Biosciences
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
08 déc. 2022 19h39 HE
|
Prometheus Biosciences
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
07 déc. 2022 16h01 HE
|
Prometheus Biosciences
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
07 déc. 2022 07h00 HE
|
Prometheus Biosciences
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all...